PolyNovo Limited

OTCPK:CALZ.F Stock Report

Market Cap: US$970.0m

PolyNovo Valuation

Is CALZ.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CALZ.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CALZ.F ($1.5) is trading below our estimate of fair value ($2.1)

Significantly Below Fair Value: CALZ.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CALZ.F?

Key metric: As CALZ.F is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CALZ.F. This is calculated by dividing CALZ.F's market cap by their current revenue.
What is CALZ.F's PS Ratio?
PS Ratio14.5x
SalesAU$103.23m
Market CapAU$1.49b

Price to Sales Ratio vs Peers

How does CALZ.F's PS Ratio compare to its peers?

The above table shows the PS ratio for CALZ.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.2x
KIDS OrthoPediatrics
3.2x16.8%US$614.8m
BVS Bioventus
1.4x6.4%US$803.4m
SMTI Sanara MedTech
4.1x16.1%US$319.6m
STAA STAAR Surgical
4.1x13.5%US$1.4b
CALZ.F PolyNovo
14.5x17.5%US$1.5b

Price-To-Sales vs Peers: CALZ.F is expensive based on its Price-To-Sales Ratio (14.5x) compared to the peer average (3.2x).

Price to Sales Ratio vs Industry

How does CALZ.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$229.37m
ARAY Accuray
0.5x5.5%US$212.19m
NVRO Nevro
0.4x2.5%US$171.62m
KEQU Kewaunee Scientific
0.6xn/aUS$122.60m
CALZ.F 14.5xIndustry Avg. 3.4xNo. of Companies50PS03.26.49.612.816+
50 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CALZ.F is expensive based on its Price-To-Sales Ratio (14.5x) compared to the US Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is CALZ.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CALZ.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CALZ.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CALZ.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.50
US$1.68
+11.7%
22.7%US$1.95US$0.68n/a9
Nov ’25US$1.30
US$1.72
+32.0%
22.7%US$2.00US$0.70n/a9
Oct ’25US$1.80
US$1.76
-1.9%
23.6%US$2.03US$0.71n/a8
Sep ’25US$1.58
US$1.76
+11.8%
23.6%US$2.03US$0.71n/a8
Aug ’25US$1.65
US$1.55
-6.1%
23.2%US$1.83US$0.69n/a8
Jul ’25US$1.68
US$1.43
-15.0%
23.6%US$1.83US$0.67n/a8
Jun ’25n/a
US$1.37
0%
22.8%US$1.79US$0.65n/a8
May ’25n/a
US$1.37
0%
22.8%US$1.79US$0.65n/a8
Apr ’25US$1.48
US$1.37
-7.2%
22.8%US$1.79US$0.65n/a8
Mar ’25US$1.44
US$1.37
-4.7%
22.8%US$1.79US$0.65n/a8
Feb ’25US$1.21
US$1.28
+5.9%
26.1%US$1.91US$0.66n/a8
Jan ’25US$0.80
US$1.24
+54.6%
29.4%US$1.84US$0.68n/a8
Dec ’24US$0.52
US$1.19
+128.9%
30.0%US$1.71US$0.63n/a8
Nov ’24n/a
US$1.19
0%
30.0%US$1.71US$0.63US$1.308
Oct ’24n/a
US$1.20
0%
30.0%US$1.73US$0.64US$1.808
Sep ’24US$1.05
US$1.35
+28.6%
29.0%US$1.86US$0.69US$1.586
Aug ’24n/a
US$1.50
0%
31.9%US$1.94US$0.60US$1.656
Jul ’24US$1.35
US$1.50
+11.5%
31.9%US$1.94US$0.60US$1.686
Jun ’24US$1.00
US$1.50
+50.5%
31.9%US$1.94US$0.60n/a6
May ’24n/a
US$1.70
0%
14.4%US$1.95US$1.28n/a6
Apr ’24US$1.15
US$1.70
+47.7%
14.4%US$1.95US$1.28US$1.486
Mar ’24US$1.24
US$1.70
+37.0%
14.4%US$1.95US$1.28US$1.446
Feb ’24US$1.20
US$1.45
+21.0%
25.9%US$1.98US$0.83US$1.215
Jan ’24US$1.19
US$1.33
+11.4%
21.0%US$1.54US$0.80US$0.805
Dec ’23US$1.40
US$1.29
-7.5%
22.6%US$1.57US$0.82US$0.524
Nov ’23n/a
US$1.07
0%
17.0%US$1.20US$0.76n/a6

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.75

7D

0.05%

1Y

-16.6%

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.27

7D

-0.3%

1Y

22.3%

Sensus Healthcare

US$141.0m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

SRTS

US$8.60

7D

-3.3%

1Y

253.9%